Medigene AG maintained guidance for the fiscal year 2023. The Management Board therefore maintains its guidance for fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.358 EUR | -2.30% | -12.75% | -14.75% |
May. 15 | Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS | CI |
May. 14 | Medigene Ag Maintains Earnings Guidance for 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.13% | 37.08M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.55% | 21.6B | |
-12.38% | 22.31B | |
-6.54% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Maintains Guidance for the Fiscal Year 2023